🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are escalating worldwide, with estimates suggesting over 82 million infections annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the face of rising global incidence, increasing antimicrobial resistance and the very limited available drugs at this time.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This approval marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Results and Global Access

Based on data published in a prominent scientific publication, zoliflodacin eradicated over nine in ten of cases of the STI. This puts it on an similar efficacy with the typical regimen, which combines an injection and a pill. The study enrolled over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to register and commercialise the drug in numerous developing nations.

Medical professionals treating patients have shared hope. Having a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is viewed as crucial to lessen the impact of the illness for patients and to halt the transmission of untreatable gonorrhoea globally.